Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04124705 · ClinicalTrials.gov registry record · Phase 2
A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 284
- Enrollment target
NCT04124705 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 284 participants.
The verdict
NCT04124705, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 284 participants
- Enrollment target
Study Summary
This study will evaluate the safe and effective dose conversion from levothyroxine (synthetic T4) therapy to Armour Thyroid therapy in participants who are on a stable dose of levothyroxine and have thyroid stimulating hormone (TSH) levels within the normal reference range.
Interventions
- DRUG Levothyroxine
- DRUG Armour® Thyroid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2019-10-11 |
| Est. Completion | 2021-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04124705
The ClinicalTrials.gov registry entry for NCT04124705 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levothyroxine is the first listed.
NCT04124705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04124705 about?
NCT04124705 is a clinical study titled "A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants". This study will evaluate the safe and effective dose conversion from levothyroxine (synthetic T4) therapy to Armour Thyroid therapy in participants who are on a stable dose of levothyroxine and have thyroid stimulating hormone (TSH) levels within the normal reference range.
What is the current status of trial NCT04124705?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 284 participants. The study started on 2019-10-11. Estimated completion is 2021-06-22.
What interventions are being tested in trial NCT04124705?
The interventions under investigation include: Levothyroxine (DRUG), Armour® Thyroid (DRUG).
Who is sponsoring clinical trial NCT04124705?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.